PharmSource – CDMO and CRO Outlook: Robust Market Conditions Augur Growth, More M&A Activity Ahead

Pages: 9 Published: November 01, 2014 Report Code: GDHCPS0006

  • Overview
  • Contents
  • Tables
  • Figures
  • Listen
    iSpeech

Emerging bio/pharmaceutical companies are benefiting from a surge in financing from venture capital, IPOs and secondary offerings. Funding raised in the first half of 2014 is double what was raised in the same period of 2013. R&D spending by global bio/pharma companies, including funds supporting emerging company partners, continues to grow but at a modest rate.

Scope

N/A

Reasons to Buy

According to the latest PharmSource Trend Report, CDMO and CRO Outlook: Robust Market Conditions Augur Growth, More M&A Activity Ahead, the impact of this increased funding is only just being felt. The report analyzes the factors that drive bio/pharmaceutical development spending and the demand for contract development services.

Table of Contents

N/A

List of Tables

N/A

List of Figures

N/A

$925

Can be used by individual purchaser only

$2775

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.